In total, 4 of 58 subjects had abnormal (i.e., strong and diffuse) p53 expression by IHC (Figure 2), which was present in patients with EIN (n = 3) and low-grade endometrioid endometrial adenocarcinoma (n = 1). Here, TP53 is linked to endometrial endometrioid adenocarcinoma.